The biopharma industry is pushing back against increased scrutiny of mergers and acquisitions from the Federal Trade Commission (FTC). More than 30 biopharma companies and industry associations announced the formation of the Partnership for the U.S. Life Science Ecosystem (PULSE) to advocate for the role of M&A activity in the biopharma sector. A M&A landscape…
Kite and Appia Bio announce on allogeneic cell therapy alliance
Gilead (NSDQ:GILD) subsidiary Kite will collaborate with Appia Bio (Culver City, Calif.) to develop engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients. To that end, they have entered into a collaboration and license agreement to develop HSC-derived cell therapies for hematological malignancies. Under the agreement, Appia Bio will lead preclinical and…